Structured Alpha LP, a fund managed by Thomvest Ventures, Inc. entered into a non-binding proposal to acquire remaining 35.97% stake in Liminal BioSciences Inc. (DB:PJ2) for $8.4 million.

Structured Alpha LP, a fund managed by Thomvest Ventures, Inc. entered into a non-binding proposal to acquire remaining 35.97% stake in Liminal BioSciences Inc. (DB:PJ2) for $8.4 million on April 4, 2023. Structured Alpha will pay $7.50 in cash per common share of Liminal BioSciences. SALP currently owns 1,987,622 common shares of Liminal Biosciences representing approximately 64.03% of the Liminal's currently outstanding common shares.

A special committee of the independent members of the Board (the "Special Committee") has been formed and will evaluate the Proposal and any viable alternatives that may be available to Liminal. The proposed transaction would be conditioned on the receipt of customary approvals, including regulatory approvals, the receipt of shareholder approvals required under applicable securities laws, including Multilateral Instrument 61-101 – Protection of Minority Security Holders in special transactions, and other conditions customary for a transaction of this nature, including confirmatory due diligence satisfactory to Thomvest. BMO Capital Markets acted as financial advisor to the special committee of Liminal BioSciences.